Organization
Stephan Grupp
5 clinical trials
Clinical trial
CD19-Directed Chimeric Antigen Receptor CD19 Redirected Autologous T Cells (CART19) for Orphan Indications of Pediatric B Cell Acute Lymphoblastic Leukemia (B ALL)Status: Recruiting, Estimated PCD: 2028-03-10
Clinical trial
Phase 1/2b Trial of Autologous Humanized CD19-Directed Chimeric Antigen Receptor T-Cells Manufactured Using the CliniMACS Prodigy Platform for the Treatment of Pediatric B Cell Acute Lymphoblastic Leukemia (B-ALL)Status: Recruiting, Estimated PCD: 2027-09-20
Clinical trial
Use of Autologous Anti-CD22 CAR T Cells (CART22-65s) Co-administered With Humanized Anti-CD19 CAR T Cells (huCART19) in Children and Young Adults With Relapsed or Refractory B-ALLStatus: Recruiting, Estimated PCD: 2027-01-15
Clinical trial
Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory NeuroblastomaStatus: Recruiting, Estimated PCD: 2025-01-30
Clinical trial
Autologous Hematopoietic Stem Cell Transplant for Children and Young Adults With Life Threatening Autoimmune DiseasesStatus: Recruiting, Estimated PCD: 2025-05-01